SEC Form 4 · accession 0001213900-26-098969
RELMADA THERAPEUTICS, INC. · RLMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sergio Traversa
Officer — Chief Executive Officer · Director
Period of report
Sep 9, 2026
Accepted (ET)
Sep 11, 2026 · 7:30 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001553643
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 9, 2026 | P | 100,000 | $4.18 | A | 1,400,000 | D | |
| Common StockF1,F3 | Sep 10, 2026 | P | 100,000 | $4.10 | A | 1,500,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
- F2Purchase prices range from $4.15 to $4.22 per share, inclusive.
- F3Purchase prices range from $4.03 to $4.11 per share, inclusive